The Pentagon’s “High-T” Mandate: Why Blanket Testosterone Screening Fails Evidence-Based Practice

 

NP CHRONICLES Clinical Education for NP Students & New Graduates

The Pentagon’s “High-T” Mandate: Why Blanket Testosterone Screening Fails Evidence-Based Practice

 

As Nurse Practitioners, we are trained to practice evidence-based medicine and exercise strict diagnostic stewardship. We know that screening asymptomatic populations without clinical indication leads to over-diagnosis, unnecessary interventions, and avoidable patient harm.

That is why the Department of Defense’s recent policy shift has clinicians across the country deeply concerned. Defense Secretary Pete Hegseth announced a new directive requiring annual testosterone screening for all active-duty male service members age 30 and older.

While initiating Testosterone Replacement Therapy (TRT) remains voluntary under the policy, this blanket screening mandate directly defies established endocrinology guidelines, risks overwhelming healthcare resources, and exposes otherwise healthy young adults to serious iatrogenic risks.

Here is a clinical breakdown of why this policy fails the standard of evidence-based practice — and what it means for healthcare systems and patient outcomes.

1. Direct Violation of Clinical Practice Guidelines

Both the Endocrine Society and the American Urological Association (AUA) maintain unambiguous, long-standing mandates against routine, population-wide screening for testosterone deficiency. As advanced practice providers, the diagnostic flaws in this blanket mandate are immediately clear:

The Symptom Prerequisite

According to Endocrine Society Clinical Practice Guidelines, a diagnosis of hypogonadism requires both biochemical evidence and distinct clinical symptoms (e.g., unexplained osteopenia, severe fatigue, or low libido). Testing asymptomatic 30-year-olds inherently creates a high statistical probability of false positives.

Diurnal Fluctuation & Stress Variables

Serum testosterone is highly volatile. Accurate assessment requires a minimum of two separate, early-morning (7:00–10:00 AM) fasting blood draws. Active-duty troops routinely face acute sleep deprivation, extreme physical exertion, and operational stress — all of which cause transient, non-clinical drops in testosterone. A single annual screen cannot differentiate between a true endocrine pathology and a tough week in the field.

 

⚠ CLINICAL NUANCE A single low reading in a fatigued, sleep-deprived service member is not a diagnosis — it's a prompt to repeat the test under controlled conditions. Reflexively confirming and treating on one draw is where the false-positive cascade begins.

 

2. Evidence-Based Alternatives: The NP Approach to Hormonal Optimization

Before jumping straight to exogenous hormones, NPs know that optimizing a patient’s metabolic health can safely and naturally reverse mild to moderate declines in testosterone. Addressing the root causes of metabolic dysfunction preserves the Hypothalamic-Pituitary-Gonadal (HPG) axis without systemic shutdown.

The Aromatase Cycle and Metabolic Weight Loss

Adipose tissue contains high concentrations of the enzyme aromatase, which actively converts circulating testosterone into estradiol.

●      Clinical goal: Losing just 10% to 15% of total body weight can significantly reduce aromatase activity, decreasing estrogen conversion and naturally driving baseline free testosterone levels back up.

●      NP intervention: Counsel patients on a sustainable, moderate caloric deficit. Avoid extreme crash diets, as prolonged starvation states elevate cortisol and actively suppress luteinizing hormone (LH) secretion.

●      Nutritional guidance: Ensure adequate dietary intake of healthy monounsaturated and saturated fats (avocados, olive oil, nuts), which serve as the essential cholesterol backbones for steroidogenesis.

Progressive Resistance Training

Physical exercise is a highly effective, non-pharmacological stimulus for transient testosterone spikes and long-term metabolic health.

●      Heavy compound lifting: Prioritize multi-joint, compound resistance movements — squats, deadlifts, and overhead presses. These recruit large muscle groups and high-threshold motor units, eliciting a much greater acute hormonal response than isolation exercises.

●      Volitional fatigue: Workouts should utilize challenging loads within a 1-to-8 or 8-to-12 repetition range to maximize mechanical tension.

●      The cortisol danger: Advise patients to avoid excessive, long-distance endurance training. Chronic, exhausting cardio floods the system with cortisol, an endocrine disruptor that directly antagonizes testosterone synthesis.

 

3. A Critical Warning on “Other Therapies”: Estrogen Blockers

In fitness subcultures and some wellness clinics, estrogen blockers (such as aromatase inhibitors like anastrozole, or SERMs like clomiphene) are frequently utilized off-label to artificially boost testosterone. As clinicians, we must exercise extreme caution here.

By blocking estrogen or stopping its production, these drugs trick the brain into thinking estrogen levels are low. The pituitary gland responds by pumping out more LH and FSH, which temporarily signals the testicles to make more testosterone.

⛔ CASE FOR CAUTION — CRASHING ESTROGEN Estrogen is absolutely vital for male health. Crashing a patient's estradiol levels destroys bone mineral density, triggers severe joint pain, negatively impacts lipid panels, and increases cardiovascular risk. Major endocrinology guidelines do not support the use of aromatase inhibitors for age-related or lifestyle-induced low testosterone in men. Relying on these off-label pharmaceuticals instead of lifestyle interventions introduces unvetted clinical risk.

 

4. Advanced Laboratory Analysis: What to Order and How to Interpret

When an asymptomatic patient is flagged with low testosterone on a routine screen — or presents with vague, non-specific symptoms like fatigue — a single “total testosterone” value is clinically insufficient. Diagnostic stewardship means evaluating the entire biochemical layout before labeling a patient deficient.

The Screening & Confirmation Pathway

1	Order Total Testosterone (TT), drawn 7:00–10:00 AM, fasting.

 

2	TT ≥ 300 ng/dL → hypogonadism unlikely; evaluate other causes of symptoms (sleep, thyroid).

 

3	TT < 300 ng/dL → repeat TT and add Free T, SHBG, LH, FSH, and prolactin.

 

4	Low result not confirmed on repeat → transient drop / false positive; no treatment indicated.

 

5	Low result confirmed on repeat → true biochemical hypogonadism; classify as primary, secondary, or functional (see matrix below).

 

What to Order: The Comprehensive Hormone Panel

●      Total Testosterone (TT): Measures bound and unbound hormone. It's the standard starting point, but can be misleading — a patient with a seemingly normal TT can still have clinical hypogonadism if bioavailable levels are depleted.

●      Sex Hormone-Binding Globulin (SHBG): Roughly 60% to 70% of circulating testosterone is bound to SHBG and biologically inactive. Obesity, insulin resistance, and high-carbohydrate diets drop SHBG; aging and hyperthyroidism raise it.

●      Free & Bioavailable Testosterone: Free testosterone (1% to 2% of total) plus albumin-bound testosterone make up the bioavailable pool — the only portion that can enter cells and exert effects. If SHBG is high, TT can look normal while Free T is profoundly low.

●      LH & FSH: Elevated LH/FSH with low testosterone indicates primary (testicular) failure. Low or inappropriately normal LH/FSH points to secondary (hypothalamic/pituitary) dysfunction, which is often reversible.

●      Prolactin: Elevated prolactin suppresses GnRH, causing secondary hypogonadism, and screens for a prolactin-secreting pituitary tumor. Evaluate via head MRI if significantly elevated (>20–30 ng/mL) or if TT is extremely low (<150 ng/dL).

How to Interpret: Differential Diagnosis Framework

Once confirmatory labs return, use this matrix to categorize the patient's condition and determine whether the path forward is permanent medical management or reversible lifestyle intervention.

 

Lab Metric	Primary Hypogonadism	Secondary Hypogonadism	Functional / Lifestyle Suppression
Total Testosterone	Low (<300 ng/dL)	Low (<300 ng/dL)	Borderline–Low (250–350 ng/dL)
Free Testosterone	Low	Low	Low to Normal (SHBG-dependent)
LH / FSH	Elevated (High)	Low or Inappropriately Normal	Low or Normal
Prolactin	Normal	Elevated (if microadenoma)	Normal
Primary Causes	Testicular trauma, viral orchitis, Klinefelter, prior chemotherapy	Pituitary adenoma, head trauma, chronic opioid use, hemochromatosis	Obesity (high aromatase), severe OSA, operational stress, extreme caloric restriction
Clinical Approach	Irreversible — requires medical TRT if symptomatic	Evaluate via head MRI if prolactin >20–30 ng/mL or TT <150 ng/dL	Fully reversible — do not start TRT; metabolic, sleep, and resistance-training protocols

 

Step-by-Step Clinical Calculation: The Vermeulen Formula

When interpreting borderline cases, do not guess at bioavailable levels. Use the Vermeulen formula to calculate free testosterone from the interaction of transport proteins — input the patient's Total Testosterone, SHBG, and Albumin into a validated clinical calculator.

A calculated free testosterone level below roughly 6.0–6.5 ng/dL (or 65 pg/mL, depending on lab reference ranges) confirms a true biochemical deficiency — even if the total testosterone number appears falsely preserved due to high SHBG.

 

5. Exposing Patients to Iatrogenic Disability Risks

Initiating TRT — or unapproved pharmaceutical interventions — in a young, healthy population carries profound long-term pathophysiological risks. For active-duty troops, these medically induced complications can result in permanent, service-connected disabilities.

●      Secondary Polycythemia & Vascular Events: Testosterone aggressively stimulates erythropoiesis. When hematocrit exceeds 54%, hyperviscosity drastically elevates the risk of DVT, pulmonary embolism, and ischemic stroke — a preventable stroke can leave a 31-year-old with permanent neurological deficits.

●      HPG Axis Suppression & Irreversible Sterility: Exogenous testosterone triggers a negative feedback loop on the hypothalamus and pituitary, shutting down endogenous LH and FSH. While often reversible, prolonged TRT can permanently damage testicular Leydig cells, causing irreversible infertility and permanent hypogonadism.

●      Exacerbation of Sleep Architecture: TRT is heavily documented to trigger or severely aggravate obstructive sleep apnea by altering central respiratory drives, often tethering a young patient to a lifetime CPAP machine.

 

6. The Bottom Line for APPs

Because these screenings and subsequent treatments are directed by military healthcare channels, any adverse outcome — a vascular event, permanent sterility, or severe sleep apnea — legally qualifies as a service-connected injury. Taxpayers will ultimately fund lifelong VA disability compensation and medical retirements for conditions that were entirely iatrogenic.

✓ CLINICAL BOTTOM LINE Population-wide screening without clinical indication drives false positives, unnecessary confirmatory testing, and a pipeline into lifelong TRT for men who were never truly deficient. As NPs, our role is to advocate for guidelines-based care: repeat and confirm before diagnosing, evaluate the full hormone panel — not TT alone — and lead with reversible lifestyle interventions before exogenous hormones. More testing does not equal better health.

 

Board Prep: Quick-Hit Review

●      Two separate, fasting AM (7–10 AM) draws — diurnal variation invalidates a single afternoon result.

●      Total testosterone < 300 ng/dL, confirmed on a second fasting AM draw.

●      High SHBG + normal TT can still equal a low Free T — always consider bioavailable testosterone in borderline cases.

●      Elevated LH/FSH → primary (testicular) failure. Low/normal LH/FSH → secondary (hypothalamic-pituitary) cause — check prolactin and consider MRI.

●      Hematocrit > 54% on TRT is a treatment-limiting threshold for polycythemia-related thrombotic risk.

●      Aromatase inhibitors and SERMs are not guideline-endorsed for age-related or lifestyle-induced low testosterone.

 

Clinician Resource: Printable Patient Handout

UNDERSTANDING YOUR TESTOSTERONE NUMBERS — WHY LIFESTYLE COMES FIRST Your recent blood test may have flagged your testosterone as “low” or “borderline.” Before jumping to medications or hormone replacement — which carry real risks and can shut down your body's natural ability to make hormones — there are proven ways to naturally support your levels. ●      Target body fat, not just weight: Excess body fat contains an enzyme that turns testosterone into estrogen. Dropping even 10% of your body weight stops this conversion and naturally raises usable testosterone. ●      Lift heavy and smart: Focus workouts on heavy, full-body exercises like squats, deadlifts, and presses rather than long, exhausting cardio sessions, which trigger stress hormones that lower testosterone. ●      Protect your sleep: Your body makes most of its daily testosterone during deep sleep. Less than 5–6 hours a night for one week can drop levels by up to 15%. Target 7–8 hours. ●      Avoid “quick fix” supplements or blockers: Over-the-counter boosters and off-label estrogen blockers can introduce unvetted risks, including joint pain, bone density loss, and cholesterol problems. Stick to natural, sustainable adjustments first.

 

References

●      Endocrine Society Clinical Practice Guidelines — Testosterone Therapy in Men with Hypogonadism.

●      American Urological Association (AUA) Guideline — Evaluation and Management of Testosterone Deficiency.

●      U.S. Department of Defense policy directive on active-duty testosterone screening (2026).

This post is intended for clinical education purposes for NP students and new graduates and does not replace individualized clinical judgment or institutional protocol.

Acute Tonsillitis and Pharyngitis: A Clinical Reasoning Guide for NPs

 

NP CHRONICLES

Clinical Practice Update for NP Students & New Graduates

Acute Tonsillitis and Pharyngitis: A Clinical Reasoning Guide for NPs

Sore throat is one of the most common chief complaints you'll see — here's how to separate self-limited viral illness from GAS infection, red-flag suppurative complications, and everything in between.

Clinical Reference: Acute tonsillitis and pharyngitis, consistent with 2012 IDSA and 2009 AHA/AAP guidelines on GAS pharyngitis (updated March 2026)

Why This Topic Deserves More Than a Quick Glance

Sore throat visits feel routine — until they aren't. Most cases of acute tonsillitis and pharyngitis are self-limited, but the differential ranges from a garden-variety rhinovirus to a peritonsillar abscess that needs an ENT consult today. Knowing which patients need a swab, which need antibiotics, and which need to go straight to the emergency department is a core skill you'll use in nearly every primary care, urgent care, or pediatric setting.

Tonsillitis (inflammation of the tonsils) and pharyngitis (inflammation of the pharynx) are often discussed together — and often occur together — but they describe distinct anatomic sites. Most cases in children and young adults are caused by either viruses or Group A Streptococcus (GAS), and distinguishing between the two drives everything downstream: testing, treatment, and patient counseling.

Who Gets What, and When

•     Viral tonsillopharyngitis accounts for the majority of cases and peaks in children under 5 and young adults.

•     GAS tonsillopharyngitis is most common in children aged 5–15 and is rare under age 2 — keep that in mind before you swab a toddler.

•     GAS infection peaks in winter and spring.

•     Bacterial causes make up roughly 15–30% of cases overall, with GAS as the dominant pathogen; less common bacterial causes include Fusobacterium necrophorum, Mycoplasma pneumoniae, and Neisseria gonorrhoeae.

Telling Viral and Bacterial Apart at the Bedside

Features That Point Toward GAS

•     Sudden onset of fever, sore throat, and painful swallowing

•     Marked pharyngeal or tonsillar erythema, edema, and exudates

•     Tender, swollen anterior cervical lymph nodes

•     Palatal petechiae

•     Notably absent: cough

•     Scarlet fever presentation: strawberry tongue and a fine, sandpaper-like rash

Features That Point Toward a Virus

•     Cough, coryza, and rhinorrhea

•     Oral ulcers or anterior stomatitis

•     Conjunctivitis

•     Diarrhea

•     Often no significant fever

One clinical pearl worth committing to memory: children under 3 rarely develop true GAS pharyngitis. When GAS does affect this age group, it's more likely to show up as fever, lymphadenopathy, mucopurulent rhinitis, and excoriated skin around the nostrils — not the classic exudative tonsillitis picture.

Red Flags You Cannot Miss

Certain features suggest a suppurative or invasive complication — peritonsillar abscess, retropharyngeal abscess, cervical lymphadenitis, mastoiditis, or, rarely, sepsis — and warrant urgent evaluation rather than routine outpatient management.

•     Trismus (difficulty opening the mouth)

•     Drooling

•     Asymmetric tonsils or a displaced uvula

•     Unilateral facial swelling

•     Muffled or “hot potato” voice

•     Any signs of sepsis or immunosuppression

Trismus plus a change in voice quality is the classic combination for a peritonsillar abscess — treat this as a same-day ENT referral, not a wait-and-see.

Diagnostic Approach: Test Smart, Not Everyone

Diagnosis is primarily clinical. Testing exists to confirm GAS infection when the clinical picture is ambiguous — not to be applied reflexively to every sore throat.

•     If red flags or airway compromise are present: skip outpatient workup and move directly to urgent management.

•     If viral features dominate: GAS testing is not routinely indicated.

•     If bacterial features dominate: consider a clinical scoring tool (modified Centor score) to decide who actually needs a rapid strep test.

•     Children under 3: routine GAS testing is not recommended given the low prevalence and low risk of rheumatic fever in this age group, unless there's a specific exposure risk (e.g., a household contact with confirmed GAS).

The Modified Centor Score

Criterion	Finding	Points
Age	3–14 years	+1
	15–44 years	0
	> 44 years	−1
Tonsillar exudate/swelling	Yes	+1
	No	0
Tender anterior cervical nodes	Yes	+1
	No	0
Temperature > 100.4°F (38°C)	Yes	+1
	No	0
Cough	Absent	+1
	Present	0

Mnemonic: M-CENTOR — Must be older than 3 years, Cough absent, Exudate on tonsils, Node enlargement, Temperature elevation, OR young/old (age-based point adjustment).

•     Score ≤ 1: no further testing needed

•     Score ≥ 2: consider rapid strep test and/or throat culture

•     Score ≥ 4: empiric antibiotics are sometimes considered, but this remains controversial and is not routinely recommended

A pediatric caveat worth remembering: the AAP's guidance, aligned with IDSA, holds that clinical scoring systems like the Centor or McIsaac criteria are not reliable enough on their own to diagnose GAS in children. Physical exam findings alone can't reliably separate viral from bacterial disease in this population — use the score to help triage who needs testing, not as a substitute for it.

Rapid Strep Test and Throat Culture

A rapid antigen detection test (RADT) is first-line in suspected bacterial disease, with results in 5–10 minutes. A positive RADT is treated as confirmatory. A negative RADT in children and adolescents should be followed by a throat culture to definitively rule out GAS — this back-up culture step is not routinely necessary in adults, given their lower risk of rheumatic fever.

Throat culture is also the right call when a patient isn't improving after 3–4 days of antibiotics, when tonsillitis is recurrent or chronic, or in adults with risk factors for invasive GAS disease.

Treatment: Supportive Care First, Antibiotics With a Reason

Every patient benefits from supportive care regardless of etiology: hydration, analgesia with acetaminophen or NSAIDs (avoid aspirin in children due to Reye syndrome risk), and consideration of a single low-dose corticosteroid in patients over age 3 to shorten symptom duration.

Antibiotics are reserved for laboratory-confirmed GAS infection. The goal isn't just symptom relief — GAS is normally self-limited on its own — it's preventing suppurative complications and, notably, acute rheumatic fever, plus reducing transmission.

Recommended Antibiotic Regimens for GAS Pharyngitis

Scenario	Drug	Duration
No penicillin allergy	Penicillin V (treatment of choice)	10 days
	Amoxicillin	10 days
	Benzathine penicillin G	Single dose
Penicillin allergy (non-anaphylactic)	Cephalexin	10 days
	Cefadroxil	10 days
History of anaphylaxis to penicillin	Clindamycin	10 days
	Azithromycin	5 days
	Clarithromycin	10 days

A practical trap to avoid: amoxicillin given empirically to a patient with undiagnosed infectious mononucleosis can trigger a diffuse maculopapular rash. Reserve antibiotics for confirmed bacterial disease whenever possible, and keep EBV on your differential in an adolescent with prominent fatigue, splenomegaly, or a negative RADT.

When Tonsillectomy Enters the Conversation

Tonsillectomy remains one of the most common pediatric ambulatory procedures. Indications include:

•     Severe tonsillar hypertrophy (“kissing tonsils”) causing obstructive sleep-disordered breathing

•     Documented recurrent throat infections or chronic tonsillitis

•     Suspected tonsillar neoplasm

•     Consideration in patients with a history of peritonsillar abscess, multiple antibiotic allergies/intolerances, or PFAPA syndrome

Defining “Recurrent”: The Paradise Criteria

“Documented recurrent throat infections” isn't just a judgment call — the AAO-HNS clinical practice guideline operationalizes it using the Paradise Criteria, which set a minimum episode frequency before tonsillectomy is considered for children ages 1–18. A child meets criteria with any one of the following patterns:

•     ≥ 7 episodes of throat infection in the past year

•     ≥ 5 episodes per year in each of the past 2 years

•     ≥ 3 episodes per year in each of the past 3 years

Each counted episode must be documented with at least one objective finding: a temperature greater than 100.9°F (38.3°C), tender cervical adenopathy, tonsillar exudate, or a positive GAS test. Note that this temperature threshold is higher than the one used in the Modified Centor score (100.4°F/38°C) — the two tools serve different purposes and shouldn't be conflated.

Children who don't meet these thresholds are managed with watchful waiting, typically for at least 12 months, before tonsillectomy is reconsidered. Surgery may still be offered to less severely affected children with modifying factors — multiple antibiotic allergies, a history of peritonsillar abscess, or a family history of rheumatic fever — after caregivers are counseled on the modest, time-limited benefit tonsillectomy provides (improvement in throat infection frequency for roughly 1–2 years post-surgery) weighed against surgical risk.

Post-operatively, avoid aspirin (bleeding risk) and counsel patients on the two windows for post-tonsillectomy hemorrhage: primary bleeding within 24 hours of surgery, and secondary bleeding roughly a week out, when the eschar sloughs. Any visible bleeding warrants urgent ENT evaluation — this is not a “watch and call if it worsens” situation.

Complications Worth Remembering

Suppurative

•     Peritonsillar, parapharyngeal, and retropharyngeal abscess

•     Otitis media, sinusitis, mastoiditis

•     Lemierre syndrome — septic thrombophlebitis of the internal jugular vein, classically from Fusobacterium necrophorum, presenting with fever, neck pain, and respiratory distress. Rare, but it's the diagnosis you don't want to miss in a young adult who isn't getting better.

Nonsuppurative (Post-Streptococcal)

•     Acute rheumatic fever — the primary reason we treat confirmed GAS with antibiotics

•     Poststreptococcal glomerulonephritis (PSGN) — antibiotic therapy does not reduce this risk, unlike rheumatic fever

•     PANDAS — abrupt-onset OCD and/or tic symptoms temporally linked to GAS infection in children; uncommon, but worth knowing the pattern

Clinical Pearls for Practice

•     Cough presence is one of your most useful discriminators — its absence raises suspicion for GAS, its presence favors a viral process.

•     Don't reflexively swab children under 3 — low pretest probability means testing does more harm than good in this group.

•     A negative RADT in a child or teen isn't the end of the workup — send the confirmatory throat culture.

•     Empiric antibiotics based on Centor score alone remain controversial; when in doubt, test before you treat.

•     Trismus + voice change = urgent same-day referral, not a routine follow-up.

•     Watch for the amoxicillin-mono rash trap in adolescents and young adults with atypical or prolonged pharyngitis.

Bottom Line

Most sore throats are viral, self-limited, and need nothing more than supportive care and good patient education about when to return. The clinical work is in reliably identifying the minority that need testing, antibiotics, or urgent referral — and in not over-treating everyone else. A careful history, a quick look for red flags, and judicious use of the modified Centor score will get you there in the vast majority of visits.

Reference

Acute tonsillitis and pharyngitis. Clinical reference consistent with the 2012 Infectious Diseases Society of America (IDSA) guideline and the 2009 American Heart Association (AHA)/American Academy of Pediatrics (AAP) guidelines on Group A streptococcal pharyngitis. Last updated March 2026.

NP Chronicles — Clinical education for NP students and new graduates since 2012.

ACOG Updates Cervical Cancer Screening Guidelines: What NPs Need to Know in 2026

 

NP CHRONICLES

Clinical Practice Update for NP Students & New Graduates

ACOG Updates Cervical Cancer Screening Guidelines: What NPs Need to Know in 2026

A practical breakdown of the new WPSI-endorsed recommendations, ACOG's key qualifications, and what changes at the point of care.

Clinical Reference: ACOG Committee Statement, Obstetrics & Gynecology 148(1):e63–e67, July 2026

Why This Update Matters

In January 2026, the Women's Preventive Services Initiative (WPSI) revised its cervical cancer screening recommendations, and the American College of Obstetricians and Gynecologists (ACOG) has now issued a qualified endorsement of that update. “Qualified” is the operative word here: ACOG agrees with the overall direction but adds specific caveats — particularly around patient-collected (self-collected) high-risk HPV (hrHPV) testing — that matter for how you counsel patients and structure your screening workflows.

For NP students and new grads, this is one of those guideline updates worth internalizing early. Cervical cancer screening is one of the most common preventive services you'll order, and the options patients are offered — and the intervals you recommend — have shifted meaningfully from what many of us learned in school.

The Core Recommendations by Age Group

Ages 21–29

•     Cytology alone every 3 years — unchanged from prior guidance.

•     hrHPV testing is not recommended as a stand-alone strategy in this age group due to high rates of transient HPV infection that would otherwise trigger unnecessary follow-up.

Ages 30–65

This is where the update carries the most practical weight. ACOG now positions clinician-collected primary hrHPV testing every 5 years as the preferred screening strategy, a shift from the prior framework in which hrHPV primary testing, co-testing, and cytology-alone were treated as essentially interchangeable options.

•     Preferred: Clinician-collected primary hrHPV testing every 5 years (FDA-approved test).

•     Acceptable alternative: Co-testing (hrHPV + cytology) every 5 years, when primary hrHPV testing isn't available or the patient chooses it after counseling.

•     Patient-collected (self-collected) primary hrHPV testing every 3 years may be offered — but only where systems exist for reliable result notification and follow-up.

•     Cytology alone every 3 years is now a fallback option, used only when hrHPV-based testing isn't accessible or the patient declines it after counseling.

Older Than 65

Routine screening can stop if the patient has adequate prior screening: three consecutive negative cytology results, or two consecutive negative co-testing results, within the past 10 years, with the most recent test within 3 years (cytology) or 5 years (co-testing). Patients without that documented history, or those at high risk, should continue screening regardless of age.

Post-Hysterectomy

Routine screening is not recommended after hysterectomy with cervix removal, provided there's no history of cervical cancer or a high-grade precancerous lesion.

The Self-Collection Caveat — Read This Twice

Patient-collected hrHPV testing is genuinely new territory for major U.S. guidelines, and it's the piece most likely to trip up a workflow if you don't plan for it. A few points ACOG is explicit about:

•     Only FDA-approved, clinician-ordered or clinician-approved kits should be used — this is not a send-home, unsupervised test.

•     Approved use is currently limited to patients aged 25–65.

•     The recommended interval for self-collection is 3 years, not 5 — the evidence base for a longer interval with self-collected samples isn't there yet.

•     Before you offer it, your practice needs a real system for documenting results, notifying patients, and tracking follow-up. ACOG is blunt that without this infrastructure, self-collection risks missed diagnoses — especially given the multi-year gap before the next screen.

Self-collection is not appropriate as a stand-alone strategy for patients with HIV, those with in-utero DES exposure, or in surveillance settings following colposcopy for atypical glandular cells or a diagnosis of adenocarcinoma in situ.

Populations Excluded From These Recommendations

These average-risk guidelines do not apply to patients with HIV, immunocompromised patients without HIV, or patients with in-utero DES exposure. These groups need individualized, more frequent surveillance — don't default to the standard intervals above for them.

Clinical Pearls for Practice

•     Cytology alone is no longer the preferred first-line option for your 30–65 population — it's now positioned as a fallback, reflecting its lower sensitivity relative to hrHPV-based strategies.

•     Document your counseling conversation when a patient chooses co-testing or cytology alone over primary hrHPV testing — the guideline frames these as informed patient choices, not just clinic default.

•     Before offering self-collection, confirm your practice or health system actually has a notification and follow-up protocol in place. If it doesn't, this isn't the year to improvise one at the point of care.

•     Equity matters here: underserved populations already screen less and face higher cervical cancer incidence and mortality. Self-collection can expand access, but only if it's paired with the same counseling and follow-up rigor as clinician-collected testing — not offered as a lesser substitute.

•     “Adequate prior screening” for stopping at 65 has a specific definition — three negative cytology results or two negative co-tests in the prior 10 years, most recent within 3–5 years. Pull the actual history before you tell a patient they're done screening.

Bottom Line

The screening menu got more nuanced, not simpler: primary hrHPV testing is now the preferred strategy for most patients aged 30–65, co-testing remains a solid alternative, cytology alone is a fallback rather than an equal option, and self-collection is a real but infrastructure-dependent addition to the toolkit. As always, the guideline's own bottom line is worth repeating to yourself before every screening visit: underscreening — not the choice of test — remains the biggest driver of preventable cervical cancer.

Reference

American College of Obstetricians and Gynecologists. Screening for cervical cancer. ACOG Committee Statement. Obstet Gynecol. 2026;148(1):e63–e67. doi:10.1097/AOG.0000000000006257.

https://www.ovid.com/10.1097/AOG.0000000000006257

NP Chronicles — Clinical education for NP students and new graduates since 2012.